- Home
- CCEC vs DAWN Comparison
CCEC vs DAWN Comparison
Compare CCEC & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- DAWN
- Stock Information
- Founded
- CCEC 2007
- DAWN 2018
- Country
- CCEC Greece
- DAWN United States
- Employees
- CCEC N/A
- DAWN N/A
- Industry
- CCEC Marine Transportation
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- CCEC Consumer Discretionary
- DAWN Health Care
- Exchange
- CCEC Nasdaq
- DAWN Nasdaq
- Market Cap
- CCEC 1.1B
- DAWN 1.3B
- IPO Year
- CCEC 2007
- DAWN 2021
- Fundamental
- Price
- CCEC $18.75
- DAWN $12.54
- Analyst Decision
- CCEC Buy
- DAWN Strong Buy
- Analyst Count
- CCEC 1
- DAWN 7
- Target Price
- CCEC $22.00
- DAWN $36.33
- AVG Volume (30 Days)
- CCEC 16.3K
- DAWN 1.2M
- Earning Date
- CCEC 01-31-2025
- DAWN 02-24-2025
- Dividend Yield
- CCEC 3.20%
- DAWN N/A
- EPS Growth
- CCEC N/A
- DAWN N/A
- EPS
- CCEC 0.85
- DAWN N/A
- Revenue
- CCEC $447,305,000.00
- DAWN $101,953,000.00
- Revenue This Year
- CCEC $17.05
- DAWN N/A
- Revenue Next Year
- CCEC $5.68
- DAWN $35.22
- P/E Ratio
- CCEC $75.99
- DAWN N/A
- Revenue Growth
- CCEC 29.66
- DAWN N/A
- 52 Week Low
- CCEC $14.45
- DAWN $11.13
- 52 Week High
- CCEC $20.26
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- CCEC N/A
- DAWN 49.68
- Support Level
- CCEC N/A
- DAWN $11.13
- Resistance Level
- CCEC N/A
- DAWN $13.30
- Average True Range (ATR)
- CCEC 0.00
- DAWN 0.51
- MACD
- CCEC 0.00
- DAWN 0.05
- Stochastic Oscillator
- CCEC 0.00
- DAWN 64.98
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the leading platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.